Julie A Kreyenbuhl1, Deborah R Medoff1, Joseph P McEvoy1, Thomas E Smith1, Ann L Hackman1, Ilana R Nossel1, Lisa B Dixon1, Susan M Essock1, Robert W Buchanan1. 1. Dr. Kreyenbuhl, Dr. Medoff, and Dr. Hackman are with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore (e-mail: jkreyenb@psych.umaryland.edu ). Dr. Kreyenbuhl and Dr. Medoff are also with the Mental Illness Research, Education and Clinical Center, Department of Veterans Affairs Capitol Healthcare Network (VISN 5), Baltimore. Dr. McEvoy is with the Department of Psychiatry, Medical College of Georgia, Augusta University, Augusta. Dr. Smith, Dr. Nossel, Dr. Dixon, and Dr. Essock are with the Department of Psychiatry, Columbia University College of Physicians and Surgeons, and with the New York State Psychiatric Institute, New York City. Dr. Buchanan is with the Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
Abstract
OBJECTIVE: This study examined the adherence of psychiatrists to the Schedule of Recommended First and Second Line Antipsychotic Medications ("Antipsychotic Schedule"), which was implemented in two Recovery After an Initial Schizophrenia Episode (RAISE) Connection Program Implementation and Evaluation Study clinics. METHODS: Sixty-five individuals with a first episode of psychosis were enrolled in the RAISE Connection Program clinics. Two psychiatrists received training and ongoing consultation on use of a shared decision-making approach to prescribing antipsychotic medications according to the Antipsychotic Schedule. Information about participants, prescribed antipsychotic medications, and completion of side-effect assessments were obtained from standardized research assessments and chart extractions. Descriptive statistics were used to characterize the extent to which patterns of antipsychotic prescribing and side-effect monitoring were consistent with the Antipsychotic Schedule. RESULTS: Ninety-two percent of participants were prescribed an antipsychotic medication and received the medication on 76%±35% of the days they were in treatment. Seventy-seven percent of participants were prescribed at least one Antipsychotic Schedule first-line antipsychotic, 20% were prescribed olanzapine, and 10% received a trial of clozapine. Regarding monitoring for metabolic side effects, 92% of participants had at least one weight recorded, 72% had at least one blood glucose measure recorded, and 62% had at least one lipid profile recorded. CONCLUSIONS: In the context of a study in which training and ongoing clinical supervision by experts was provided to psychiatrists and shared decision making was encouraged, antipsychotic prescribing patterns closely adhered to recommendations established by the RAISE Connection Program.
OBJECTIVE: This study examined the adherence of psychiatrists to the Schedule of Recommended First and Second Line Antipsychotic Medications ("Antipsychotic Schedule"), which was implemented in two Recovery After an Initial Schizophrenia Episode (RAISE) Connection Program Implementation and Evaluation Study clinics. METHODS: Sixty-five individuals with a first episode of psychosis were enrolled in the RAISE Connection Program clinics. Two psychiatrists received training and ongoing consultation on use of a shared decision-making approach to prescribing antipsychotic medications according to the Antipsychotic Schedule. Information about participants, prescribed antipsychotic medications, and completion of side-effect assessments were obtained from standardized research assessments and chart extractions. Descriptive statistics were used to characterize the extent to which patterns of antipsychotic prescribing and side-effect monitoring were consistent with the Antipsychotic Schedule. RESULTS: Ninety-two percent of participants were prescribed an antipsychotic medication and received the medication on 76%±35% of the days they were in treatment. Seventy-seven percent of participants were prescribed at least one Antipsychotic Schedule first-line antipsychotic, 20% were prescribed olanzapine, and 10% received a trial of clozapine. Regarding monitoring for metabolic side effects, 92% of participants had at least one weight recorded, 72% had at least one blood glucose measure recorded, and 62% had at least one lipid profile recorded. CONCLUSIONS: In the context of a study in which training and ongoing clinical supervision by experts was provided to psychiatrists and shared decision making was encouraged, antipsychotic prescribing patterns closely adhered to recommendations established by the RAISE Connection Program.
Authors: Kenneth L Subotnik; Keith H Nuechterlein; Joseph Ventura; Michael J Gitlin; Stephen Marder; Jim Mintz; Gerhard S Hellemann; Leslie A Thornton; Indira R Singh Journal: Am J Psychiatry Date: 2011-01-04 Impact factor: 18.112
Authors: Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary Koch; Robert M Hamer Journal: Neuropsychopharmacology Date: 2003-03-26 Impact factor: 7.853
Authors: Lisa B Dixon; Howard H Goldman; Melanie E Bennett; Yuanjia Wang; Karen A McNamara; Sapna J Mendon; Amy B Goldstein; Chien-Wen J Choi; Rufina J Lee; Jeffrey A Lieberman; Susan M Essock Journal: Psychiatr Serv Date: 2015-03-16 Impact factor: 3.084
Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: Diana O Perkins; Hongbin Gu; Peter J Weiden; Joseph P McEvoy; Robert M Hamer; Jeffrey A Lieberman Journal: J Clin Psychiatry Date: 2008-01 Impact factor: 4.384
Authors: Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Delbert G Robinson; Nina R Schooler; Christoph U Correll; Majnu John; Benji T Kurian; Patricia Marcy; Alexander L Miller; Ronny Pipes; Madhukar H Trivedi; John M Kane Journal: Am J Psychiatry Date: 2017-09-15 Impact factor: 18.112
Authors: Jane E Hamilton; Devika Srivastava; Danica Womack; Ashlie Brown; Brian Schulz; April Macakanja; April Walker; Mon-Ju Wu; Mark Williamson; Raymond Y Cho Journal: J Behav Health Serv Res Date: 2019-07 Impact factor: 1.505
Authors: Franco Mascayano; Iruma Bello; Howard Andrews; Diego Arancibia; Tamara Arratia; María Soledad Burrone; Sarah Conover; Kim Fader; Maria Jose Jorquera; Mauricio Gomez; Sergio Malverde; Gonzalo Martínez-Alés; Jorge Ramírez; Gabriel Reginatto; Alexandra Restrepo-Henao; Robert A Rosencheck; Sara Schilling; Thomas E Smith; Gonzalo Soto-Brandt; Eric Tapia; Tamara Tapia; Paola Velasco; Melanie M Wall; Lawrence H Yang; Leopoldo J Cabassa; Ezra Susser; Lisa Dixon; Rubén Alvarado Journal: Trials Date: 2022-09-05 Impact factor: 2.728